A $150 million venture capital fund managed on behalf of a not-for-profit health system makes direct investments in innovative healthcare companies. Typical equity allocations range from $5-8 million over the life of a company. The firm typically co-invests with other VC funds but is also open to leading in a financing round. The firm is looking primarily for opportunities across the US, and the firm would consider international companies with strong US advocacy and technology that can be deployed to the US market.

The firm is looking for innovative medical technologies that are in line with the organization’s mission, improve quality and convenience, lower cost and improve health outcomes. Examples may include patient management systems for healthcare providers, home care systems, or monitoring devices for chronic disease management. The firm typically works with mature companies with revenue, consumer traction, or some validation on their technology.

The firm is looking for solid management teams that show track records of success. The firm provides healthcare system expertise to portfolio companies to refine existing solutions, while expanding their adoption within and beyond its healthcare system.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices across the US, Europe and Asia is currently looking to make new investments into biopharmaceutical and medical device companies from its two funds. The firm looks to invest in early stage companies and can provide up to about $17 million to a company over the lifetime of the investment. The firm is most interested in companies based in the US, Canada, Ireland, Singapore and will also consider exceptional opportunities elsewhere in Europe and in Asia. The firm plans to make approximately 8 new investments over the next 6-9 months.

The firm is interested in companies developing either biopharmaceuticals or medical devices. For biopharmaceuticals, the firm is interested in all modalities including small molecules, biologics, and cell and gene therapies. The firm is primarily interested in platform companies with the potential for multiple assets and strongly prefers technologies to be 1st in class or best in class, often originating from breakthrough chemistry or biology discoveries. The firm is looking for companies with assets in discovery through Phase 1 clinical trials. For medical devices, the firm is primarily interested in companies working on devices that have the ability to treat drug-like markets, as well as devices for self-pay markets. The firm is indication-agnostic in both biopharmaceuticals and devices.

The firm can both lead and co-lead investments, with a preference for taking a board seat. The firm prefers working with management teams with positive track records; however, they are open to working with incomplete or non-permanent management teams as well, especially for very early stage opportunities. The investment team has extensive operating experience and deep networks, which they can leverage to support companies as needed.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An asset management group based in China operates a USD fund of $50 million that invests in healthcare and technology startups. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, and healthcare IT products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that have completed a prototype and obtained FDA clearance or are ready for FDA submission. The firm is agnostic to indication areas.

The firm is looking for experienced management teams. The firm can leverage its innovation center to assist with commercialization in the China market. The firm my request distribution rights and board representation post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a pharmaceutical company seeks to make strategic investments into early-stage companies that are aligned with its parent firm’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. The firm benefits from deep connections into its parent firm’s global research and development centers, and is well placed to nurture innovative pharmaceutical companies and to connect these into the parent organization.

The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, and CNS. The firm is also interested in breakthrough platforms technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital company based the southeast USA manages several funds, with its most recent fund having had its first close in 2017. The firm looks to provide up to $3-4 million of preferred equity capital in the initial round and up to $6 million over the life of the investment. The firm is very flexible in terms of period to exit but generally looks to exit in around 5 years. The firm will consider companies globally.

The firm is currently looking for companies developing Therapeutics and Medical Technology. Within therapeutics, which is the firm’s primary focus, companies with an asset anywhere from pre-clincal with positive animal data to phase II will be considered. The firm is generally open to all technology types and indications with the exception of wound care and psychiatry. Within devices, the firm is currently looking for market approved product with early revenue; however, devices are not an investment priority at present. The firm is looking for companies targeting true un-met medical needs where either no treatment currently exists or the existing standard of care is wrought with side-effects and other impediments to quality care.

The firm does not have any specific requirement for a firm’s management team although they are an active investor looking to take a seat on the company’s board. The firm generally tends to lead or co-lead investments into selected companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family investment trust based in the Boston area invests in early-stage healthcare and life sciences startups. The firm makes seed investments usually in the range of $50K-$250K initially and typically participates in future financing rounds. Investments may come in the form of straight equity or convertible notes depending on the deal. In addition to capital, the group looks to leverage years of experience in the biotech and healthcare industry and add value to portfolio companies through clinical and regulatory strategy, product launch and commercial strategy as well as corporate governance. The group may lead or syndicate rounds and is open to companies on a global basis.

The firm is fairly agnostic in terms of sectors and indications and is interested in therapeutics, medical devices, diagnostics and healthcare IT. As for therapeutics, the group is only interested in first-in-class / best-in-class compounds and does not evaluate iterative or repurposed assets (such as 505(b)(2) regulatory pathways). The group is also interested in medical devices and diagnostic technologies and has specific expertise in the orthopedic space, where several of the groups investments lie. Healthcare IT is also a focus area with most interest in consumer-oriented digital therapies, as opposed to enterprise software solutions.

The firm places a large emphasis on the management team / founders and looks to completely understand the company’s business prior to investment. The group often seeks a board seat along with an investment, but it is not necessarily required

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global venture capital firm based in Menlo Park, California with additional offices worldwide has approximately $3.5 billion in total assets across 10 funds, and the most recent fund closed at over $600 million. The firm focuses on making equity investments into the life science and technology spaces from seed to late venture stage. The investment size is varied, and typically it ranges from $1 million to $20 million. The firm will invest in companies based in the US, India and Israel.

The firm is currently looking for new opportunities in the Biotech Therapeutics, Medical Devices and Healthcare IT sectors. The firm will also consider Diagnostics, but that will not be its focus. For Therapeutics and Medical Devices, the firm is extremely opportunistic in terms of subsectors and indications. The firm is interested in companies targeting orphan diseases. The firm is generally looking for companies in the clinical stage of development, but it also considers preclinical companies one or two years from clinics, as well as near companies near commercial stages dependent on the case.

The firm primarily invests in private companies, and considers pre-revenue companies. The firm doesn’t have specific requirements for company’s management team or revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com